Kidney Disease Medications: A Simple Overview

Kidney disease medications encompass a broad and important category of treatments that slow the progression of chronic kidney disease (CKD), manage its complications, and reduce the risk of the cardiovascular events that are the leading cause of death in people with impaired kidney function. Understanding what these medications do, why they are prescribed, and what monitoring they require is one of the most practical steps a person with CKD can take toward active participation in their own care. People with CKD commonly take multiple medications — for blood pressure, blood sugar, fluid management, bone health, anemia, and acid-base balance — each targeting a specific complication of reduced kidney function or a modifiable driver of CKD progression. The number of medications can be daunting, and the reasoning behind each is not always well explained at clinical appointments. This guide provides a simple, accessible overview of the most important medication classes used in kidney disease: what they are, what they do, and what patients should know about taking them safely.

The goals of medication management in CKD are: (1) slow the rate of decline in kidney function (glomerular filtration rate, GFR) so that kidney failure is delayed as long as possible; (2) reduce proteinuria (protein in the urine), which is both a marker and a driver of CKD progression; (3) manage blood pressure to the target range that best protects the kidneys; (4) control blood glucose in people with diabetic kidney disease; (5) prevent and treat the metabolic complications of CKD — anemia, metabolic acidosis, hyperphosphatemia, secondary hyperparathyroidism, and hyperkalemia; and (6) reduce the elevated cardiovascular risk that accompanies CKD. The medication landscape for CKD has changed substantially in the past decade with the addition of SGLT2 inhibitors and GLP-1 receptor agonists to the standard of care, which have demonstrated kidney-protective effects beyond blood pressure and blood glucose control in large randomized trials. Understanding the expanding role of newer agents alongside the established medications helps people with CKD engage in informed conversations with their nephrologist and primary care provider about their treatment plan.

Blood Pressure Medications in Kidney Disease

Blood pressure control is the single most important modifiable factor for slowing CKD progression, and the medications used to achieve it are the cornerstone of kidney disease treatment. Hypertension both causes CKD (hypertensive nephropathy) and accelerates the progression of all forms of CKD by increasing intraglomerular pressure and promoting glomerulosclerosis. The current target blood pressure in people with CKD is below 130/80 mmHg — a target that typically requires two or more antihypertensive agents rather than monotherapy. ACE inhibitors (angiotensin-converting enzyme inhibitors — lisinopril, ramipril, enalapril, perindopril) and ARBs (angiotensin receptor blockers — losartan, valsartan, olmesartan, irbesartan) are the first-line antihypertensives for CKD patients with proteinuria, since they reduce intraglomerular pressure beyond their blood pressure-lowering effect by blocking the renin-angiotensin-aldosterone system (RAAS). They are the only antihypertensive class proven to reduce proteinuria and slow GFR decline independently of blood pressure reduction. Detailed information about ACE inhibitors and ARBs in kidney disease — including their mechanism, monitoring requirements, and when each is preferred — is available in the ACE inhibitors and ARBs for kidney health guide on Horizon Health Guide. Diuretics are frequently needed in CKD to manage fluid overload and contribute to blood pressure control; their specific role and risks in kidney disease are covered in the diuretics and kidney health guide. Calcium channel blockers (amlodipine, felodipine) are often added as second-line antihypertensives in CKD when ACE inhibitor or ARB monotherapy is insufficient; they do not reduce proteinuria independently but are effective blood pressure-lowering agents with good tolerability in CKD. The full evidence base for blood pressure medication in CKD, including target BP recommendations from KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, is covered in the blood pressure medications and kidney protection guide.

SGLT2 Inhibitors: The Newest Kidney-Protective Medications

Sodium-glucose cotransporter-2 (SGLT2) inhibitors — empagliflozin, dapagliflozin, canagliflozin — represent the most significant advance in kidney-protective pharmacotherapy in a generation. Originally developed as glucose-lowering agents for type 2 diabetes, SGLT2 inhibitors were found in large cardiovascular and kidney outcome trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) to substantially reduce the progression of CKD, decrease proteinuria, and lower the risk of kidney failure and cardiovascular death in people with CKD — and these kidney-protective effects are present independent of whether the person has diabetes. SGLT2 inhibitors work in the kidney by reducing the reabsorption of sodium and glucose in the proximal tubule, which reduces intraglomerular hypertension through a tubuloglomerular feedback mechanism (reduced sodium delivery to the macula densa triggers afferent arteriolar vasoconstriction, lowering glomerular filtration pressure), and by direct anti-inflammatory and anti-fibrotic effects in the kidney tubule. Dapagliflozin is now approved specifically for CKD regardless of diabetes status, and KDIGO guidelines recommend SGLT2 inhibitors for all people with CKD and an eGFR above 20 mL/min/1.73m² who can tolerate them. The SGLT2 inhibitor mechanism, evidence base, and specific kidney health benefits are covered in the SGLT2 inhibitors and kidney health guide. For the broader context of diabetes medication management in CKD, including how SGLT2 inhibitors fit into the overall diabetes treatment strategy, the diabetes medications and kidney protection guide provides the comprehensive clinical framework. For authoritative patient information on CKD medications, the NIDDK CKD management resource provides accessible evidence-based guidance.

Medications for Metabolic Complications of CKD

As CKD progresses, the kidneys lose their ability to maintain normal metabolic balance — the filtering and regulatory functions of the kidney that maintain acid-base, phosphate, potassium, and erythropoietin levels all deteriorate, and medications are required to compensate for these failures. Sodium bicarbonate (oral bicarbonate supplementation) is used to treat metabolic acidosis — the build-up of acid in the blood that occurs as the kidney’s ability to excrete acid and regenerate bicarbonate declines in CKD stages 3–5. Treating metabolic acidosis has been shown in multiple studies to slow the rate of GFR decline (acid itself damages tubular cells and promotes interstitial fibrosis), reduce muscle protein catabolism, improve bone health, and reduce the risk of hospitalizations in CKD; KDIGO now recommends treating metabolic acidosis when serum bicarbonate falls below 22 mmol/L. Phosphate binders (calcium carbonate, sevelamer, lanthanum carbonate, sucroferric oxyhydroxide) are used from CKD stage 3b–4 onward to reduce dietary phosphate absorption from the gut, preventing the hyperphosphatemia that drives secondary hyperparathyroidism, vascular calcification, and progressive CKD. Phosphate binders must be taken with meals to be effective, since they bind phosphate in the gut during digestion; the choice between calcium-containing and non-calcium binders is guided by serum calcium levels, since calcium-containing binders increase calcium load and may promote vascular calcification in patients with high serum calcium. Vitamin D analogs (calcitriol, alfacalcidol, paricalcitol) are used in CKD to treat the secondary hyperparathyroidism that develops as reduced kidney activation of vitamin D (from 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, which the kidney performs) drives PTH elevation, bone loss, and vascular calcification. Erythropoiesis-stimulating agents (ESAs) — epoetin alfa, darbepoetin alfa — and intravenous iron supplementation are used to treat the normocytic anemia of CKD, which results from reduced erythropoietin production by the fibrotic kidney and from functional iron deficiency; treating CKD anemia improves energy, exercise tolerance, and quality of life, though hemoglobin targets must be carefully managed to avoid increased cardiovascular risk from overcorrection. The authoritative clinical framework for CKD management including metabolic complications is provided by the KDIGO CKD guidelines and the StatPearls CKD review.

Medication Safety and Monitoring in Kidney Disease

People with CKD face a particular challenge with medication safety — many commonly used drugs are renally excreted or nephrotoxic, and doses that are safe in normal kidney function can accumulate to toxic levels or cause acute kidney injury in patients with reduced eGFR. Understanding the most important medication safety principles for kidney patients is as important as knowing what medications to take. NSAIDs (non-steroidal anti-inflammatory drugs) — ibuprofen, naproxen, diclofenac, and related agents — are among the most nephrotoxic commonly used drugs and should generally be avoided in CKD; they reduce renal prostaglandin synthesis, which normally maintains renal blood flow, causing acute-on-chronic kidney injury particularly in patients with reduced kidney reserve. The specific risks and safer alternatives to NSAIDs in CKD are detailed in the NSAIDs and kidney risk guide. Contrast agents used in CT and angiography procedures carry a risk of contrast-induced nephropathy in patients with CKD stage 3 and above; the risk is highest with ionic high-osmolality contrast and lowest with non-ionic iso-osmolality agents given with adequate hydration. Patients with CKD should always inform their radiologist and proceduralist of their kidney function (eGFR) before any imaging with contrast so that risk-mitigation strategies can be applied. Regular laboratory monitoring — eGFR and creatinine, serum potassium (particularly on ACE inhibitors, ARBs, and potassium-sparing diuretics), bicarbonate, phosphate, PTH, hemoglobin, and urine albumin-to-creatinine ratio — is the foundation of safe medication management in CKD and allows dose adjustments, medication changes, and early detection of complications before they become clinically significant. The comprehensive guide to the medication risks that kidney patients face — including over-the-counter agents, supplements, and contrast — is covered in the medication safety for kidney patients guide. For patients who want to understand their kidney health numbers and what monitoring tests mean, the kidney health numbers guide on Horizon Health Guide provides a clear explanation of the key laboratory values that guide CKD management decisions.

Sources: NIDDK — Managing CKD · KDIGO CKD Guidelines · StatPearls — CKD

How Medications Slow CKD Progression: The Mechanisms

Understanding how kidney disease medications slow the progression of CKD is important for people with CKD who want to understand why adherence to their treatment plan matters — these medications are not simply managing symptoms, but actively intervening in the biological processes that destroy kidney tissue. The two dominant pathological processes in CKD progression are glomerular hypertension (elevated pressure within the kidney’s filtration units — the glomeruli) and tubulointerstitial fibrosis (scarring of the kidney’s tubular tissue and surrounding interstitium, driven by inflammation, oxidative stress, and maladaptive repair). Both processes cause irreversible loss of functional nephrons — the individual filtration units that make up the kidney — and since lost nephrons cannot be regenerated in adult humans, preventing their loss is the central objective of CKD management.

ACE inhibitors and ARBs reduce glomerular hypertension by dilating the efferent arteriole (the blood vessel leaving the glomerulus), which reduces the pressure gradient across the glomerular filtration membrane. This lowers the mechanical stress on glomerular podocytes — the specialized cells whose foot processes form the filtration barrier — reducing podocyte injury and the consequent proteinuria. Proteinuria itself is nephrotoxic: albumin and other proteins filtered in excess are reabsorbed by proximal tubular cells, which are damaged by protein overload and respond by releasing pro-inflammatory and pro-fibrotic cytokines (TGF-β, NF-κB-mediated chemokines) that recruit macrophages and activate myofibroblasts, driving tubulointerstitial fibrosis. By reducing proteinuria, RAAS blockers interrupt this tubular inflammation-fibrosis cycle and preserve tubular cell viability. SGLT2 inhibitors reduce glomerular hypertension through a different mechanism — the tubuloglomerular feedback pathway: by blocking sodium-glucose reabsorption in the proximal tubule, they increase sodium delivery to the distal tubule and the macula densa, which triggers afferent arteriolar vasoconstriction through the tubuloglomerular feedback reflex, reducing glomerular filtration pressure. Additionally, SGLT2 inhibitors reduce proximal tubular oxygen consumption (since they block the energetically demanding SGLT2 cotransporter), potentially reducing tubular hypoxia — a driver of fibrosis in the CKD kidney. The combined hemodynamic and metabolic mechanisms of SGLT2 inhibitors explain why they confer kidney protection on top of and independent of RAAS blockade. Strict blood pressure control protects the kidney by reducing the systemic hypertension that, transmitted across the renal vasculature, contributes to glomerular hypertension even when RAAS blockade is in place — this is why achieving the blood pressure target (below 130/80 mmHg) with additional antihypertensive agents is clinically important rather than optional. Understanding the tissue-level mechanisms of these medications reinforces why adherence matters: each missed dose of an ACE inhibitor or SGLT2 inhibitor allows glomerular pressure to rise toward unprotected levels, and the cumulative hemodynamic stress of poor adherence contributes to faster GFR decline over months and years. The National Kidney Foundation’s CKD patient education provides additional accessible explanations of how kidney damage progresses and what treatments are aimed at preventing it.

Managing Multiple Medications: Polypharmacy and Adherence in CKD

People with CKD are among the most heavily medicated patient groups in medicine — the average person with CKD stage 3–4 takes 7–12 medications, and those with CKD stage 5 or undergoing dialysis may take 15 or more. This level of polypharmacy creates substantial challenges for adherence, medication reconciliation, drug interactions, and the risk of medication-related adverse events. Adherence to CKD medications — consistently taking the correct dose at the correct time — is the single most controllable determinant of whether medications provide their proven kidney-protective benefit, and non-adherence is common: studies in CKD populations consistently find that 30–50% of patients miss doses regularly, with the complexity of the medication regimen being one of the strongest predictors of non-adherence. Simplifying medication regimens where possible — using once-daily formulations, combination pills (e.g., fixed-dose ACE inhibitor plus calcium channel blocker), and organizing medications into blister packs or pill organizers with a consistent daily routine — is one of the most evidence-based interventions for improving adherence in CKD. For individuals managing multiple medications for CKD alongside medications for other conditions, the risk of drug interactions is significant and requires active management. ACE inhibitors and ARBs increase the risk of hyperkalemia (elevated serum potassium) — a risk that is amplified when combined with potassium-sparing diuretics (spironolactone, eplerenone), potassium supplements, or in patients with advanced CKD whose renal potassium excretion is already impaired; regular monitoring of serum potassium is essential in these combinations. Potassium binders — patiromer and sodium zirconium cyclosilicate — are newer agents that allow people with CKD and hyperkalemia tendency to continue RAAS blockade (with its kidney-protective benefits) rather than being forced to stop it due to potassium concerns; they work by binding potassium in the gastrointestinal tract and preventing its absorption, providing a pharmacological solution to the adherence-versus-safety tension that hyperkalemia creates in RAAS-treated CKD patients. Metformin, which is widely used in type 2 diabetes, requires dose adjustment and eventual discontinuation as CKD progresses — it is generally safe at eGFR 45–60 with careful monitoring, used with caution at eGFR 30–45, and should be stopped below eGFR 30 due to the risk of lactic acidosis from impaired renal clearance; the adjustments required as kidney function declines make regular eGFR monitoring important for all diabetic patients on metformin. For the full clinical picture of how diabetes medications are adjusted and safely used as kidney function declines — including metformin, SGLT2 inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists — the diabetes medications and kidney protection guide provides the comprehensive clinical framework.

The Role of Supplements in Kidney Disease: What to Avoid

The supplement industry is a significant source of medication safety risk for people with CKD, who are often drawn to complementary and alternative health products by the desire to do something beyond their prescribed medications and by the perception that natural or herbal products are safe. In reality, many supplements carry significant nephrotoxic or pharmacokinetic risks in CKD that are not disclosed on their packaging and that most people are unaware of. Herbal products containing aristolochic acid — found in many traditional Asian herbal preparations including those used in some weight-loss products — are severely nephrotoxic and cause an irreversible rapidly progressive tubulointerstitial nephritis (aristolochic acid nephropathy, also called Chinese herb nephropathy) that has caused kidney failure in previously healthy individuals; they are absolutely contraindicated in CKD. High-dose vitamin C supplementation (above 250mg/day) increases urinary oxalate excretion and can precipitate oxalate nephropathy — calcium oxalate crystal deposition in the tubules — in susceptible individuals with CKD; many high-dose vitamin C supplements and IV infusion products carry this risk. Creatine supplements, used in bodybuilding and athletic contexts, can elevate serum creatinine by non-renal mechanisms (creatine is converted to creatinine) — this can confound the interpretation of serum creatinine as a kidney function marker and is best avoided in CKD where accurate creatinine measurement is clinically important. Phosphorus-containing supplements and many protein powders contain significant phosphate loads that are problematic for CKD patients with hyperphosphatemia; the phosphate content of supplements is often not well disclosed, and the label term “phosphoric acid” or various phosphate salts can represent significant phosphate additions to the already restricted dietary phosphate intake of CKD patients on phosphate binders. Potassium-containing supplements and many electrolyte drinks contain potassium that can precipitate hyperkalemia in CKD patients already at risk. The comprehensive review of supplements and their specific risks for kidney patients — including which supplements have limited evidence for harm and can be used with appropriate monitoring — is detailed in the kidney patients supplement review guide. The general principle that a nephrologist should review all supplements — prescribed, over-the-counter, and herbal — before a CKD patient takes them is not excessive caution but an evidence-based safety practice given the breadth of supplement-related kidney harm documented in the nephrology literature. The NIDDK dietary guidance for CKD provides authoritative patient education on safe dietary and nutritional choices in kidney disease.

When to See a Nephrologist About Your Medications

Primary care providers and general practitioners manage the majority of people with CKD stages 1–3, and for many of these patients, the medication regimen is straightforward — RAAS blockade for proteinuric CKD, blood pressure control to target, and an SGLT2 inhibitor if tolerated. But there are specific clinical situations in which nephrology consultation is important for medication management, and recognizing these situations allows people with CKD to advocate for the appropriate level of specialist involvement in their care. A nephrologist should be involved in medication management when: the eGFR is declining faster than expected despite seemingly adequate blood pressure and glucose control (suggesting inadequate treatment, treatment-resistant disease, or an additional treatable cause); when hyperkalemia is limiting the use of RAAS blockers, since potassium binders may allow continued RAAS use that the primary care provider may not prescribe independently; when anemia is not responding to oral iron and oral erythropoiesis support, since the decision to start IV iron or an ESA and to set the hemoglobin target requires specialist oversight; when metabolic acidosis is not correcting with standard sodium bicarbonate dosing; when phosphate, PTH, and vitamin D levels are becoming difficult to balance (the CKD-mineral bone disorder management becomes complex in CKD stages 4–5 and requires specialist expertise); and when the medication list has grown to the point where drug interactions, dose adjustments for declining eGFR, and polypharmacy management exceed what is feasible in a standard primary care visit. For people with CKD stages 4–5 — eGFR below 30 mL/min/1.73m² — nephrology co-management is standard of care in most guidelines, including KDIGO, given the complexity of metabolic management and the need for preparation for kidney replacement therapy if progression to kidney failure occurs. The relationship between your primary care provider and a nephrologist in managing your CKD medications is a collaborative one — primary care for general health maintenance and the broader cardiovascular risk management, nephrology for the kidney-specific complications and the specialist-guided decisions about medication changes as CKD progresses. For the overarching framework of how kidney disease is staged, monitored, and managed through its progression, the understanding CKD stages guide on Horizon Health Guide provides the clinical foundation that contextualizes why medication management changes at each stage of kidney disease.